Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Poor social support and loneliness in chronic headache: Prevalence and effect modifiers

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reply: The role of neurovascular contact in patients with multiple sclerosis

    Research output: Contribution to journalLetterResearchpeer-review

  1. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  2. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them.

METHODS: We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed.

RESULTS: Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks.

CONCLUSION: These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks.Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740).

Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume41
Issue number11-12
Pages (from-to)1262-1267
Number of pages6
ISSN0333-1024
DOIs
Publication statusPublished - Oct 2021

    Research areas

  • episodic migraines, erenumab, monthly migraine attacks, monthly migraine days, STRIVE study

ID: 65607335